BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities

Cancer Science

Volumn 102, Issue 1, 2011, Pages 182-191

  Hu, Chih Bo ^a   Chen, Ching Ping ^a   Yeh, Teng Kuang ^a   Song, Jen Shin ^a   Chang, Chi Yen ^a   Chuu, Jiunn Jye ^a,b   Tung, Fei Feng ^a,c   Ho, Pei Yin ^a   Chen, Tung Wei ^a,d   Lin, Chi Hung ^d   Wang, Min Hsien ^a   Chang, Kai Yen ^a   Huang, Chen Lung ^a   Lin, Heng Liang ^a   Li, Wen Tai ^a   Hwang, Der Ren ^a   Chern, Jyh Haur ^a   Hwang, Ling Ling ^c   Chang, Jang Yang ^a   Chao, Yu Sheng ^a   Chen, Chiung Tong ^a,c   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BPR 0C261; CISPLATIN; COLCHICINE; DOXORUBICIN; MATRIGEL; N (3 METHYL 5 ISOTHIAZOLYL) 2 1 [(3 METHYL 5 ISOXAZOLYL)METHYL] 1H 3 INDOLYL 2 OXOACETAMIDE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIMITOTIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DISRUPTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLONOGENIC ASSAY; COLORECTAL TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL LINE; MALE; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE ASSEMBLY; MOUSE; NASOPHARYNX TUMOR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STOMACH TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DOGS; HUMANS; INDOLES; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED STRAINS; MICROTUBULES; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 78650197530     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01744.x     Document Type: Article

References (42)

1. Budman D. Vinorelbine (Navelbine): a third-generation Vinca alkaloid. Cancer Invest 1997; 15: 475-90.
2. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003; 63: 6026-31.
3. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003; 89(Suppl 3): S9-15.
4. Goncalves A, Braguer D, Kamath K et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001; 98: 11737-42.
5. Kavallaris M, Tait AS, Walsh BJ et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-9.
6. Dumontet C, Isaac S, Souquet P et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005; 92: E25-30.
7. Ferlini C, Raspaglio G, Mozzetti S et al. The seco-taxane IDN5390 is able to target class III b-tubulin and to overcome paclitaxel resistance. Cancer Res 2005; 65: 2397-405.
8. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5: 65-71.
9. Carlson RO. New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 2008; 17: 707-22.
10. Simoni D, Romagnoli R, Baruchello R et al. Novel combretastatin analogues endowed with antitumor activity. J Med Chem 2006; 49: 3143-52.
11. Tron G, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani A. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006; 49: 3033-44.
12. Gourdeau H, Leblond L, Hamelin B et al. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4, 5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol Cancer Ther 2004; 3: 1375-84.
13. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
14. Hung H. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. Mol Cancer Ther 2007; 6: 2149-57.
15. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
16. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008; 13: 845-58.
17. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007; 64: S4-7.
18. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 2003; 7: 5-9.
19. Ho PY, Yeh TK, Yao HT et al. Enhanced oral bioavailability of paclitaxel by D-a-tocopheryl polyethylene glycol 400 succinate in mice. Int J Pharm 2008; 359: 174-81.
20. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 2006; 6: 973-82.
21. Bacher G, Nickel B, Emig P et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001; 61: 392-9.
22. Li WT, Hwang DR, Chen CP et al. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. J Med Chem 2003; 46: 1706-15.
23. Park S-Y, Lam W, Cheng Y-C. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002; 62: 459-65.
24. Kuo CC, Hsieh HP, Pan WY et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004; 64: 4621-8.
25. Li WT, Hwang DR, Song JS et al. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents. J Med Chem 2010; 53: 2409-17.
26. Singer WD, Hersh RT, Himes RH. Effect of solution variables on the binding of vinblastine to tubulin. Biochem Pharmacol 1988; 37: 2691-6.
27. Kato Y, Salumbides BC, Wang XF et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007; 6: 70-81.
28. Yeh TK, Li CM, Chen CP et al. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacol Res 2010; 61: 108-15.
29. Huang YC, Chen CT, Chen SC et al. A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration. Pharm Res 2005; 22: 636-46.
30. Myers T, Chengedza S, Lightfoot S et al. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs 2009; 27: 304-18.
31. Wang H-S, Hwang L-L, Sue H-F, Lee K-M, Chen C-T. A simple quantitative method for evaluation of angiogenesis activity. Assay Drug Dev Technol 2004; 2: 31-8.
32. Kwak HJ, Park MJ, Park CM et al. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 2006; 118: 2711-20.
33. Lee SH, Yoo SD, Lee KH. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 724: 357-63.
34. Chang YW, Chen WC, Lin KT et al. Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of BPR0L075, a novel antimicrotuble agent, in rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 846: 162-8.
35. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
36. Ranade VV. Drug delivery systems 5A. Oral drug delivery. J Clin Pharmacol 1991; 31: 2-16.
37. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 2000; 11: 207-14.
38. Brown D, Goosen TC, Chetty M, Hamman JH. Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line. Eur J Pharm Biopharm 2003; 56: 159-65.
39. Dahl SG, Strandjord RE. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 1977; 21: 437-48.
40. Mabuchi S, Terai Y, Morishige K et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14: 7781-9.
41. Xu L, Zuch CL, Lin YS, Modi NB, Lum BL. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. Cancer Chemother Pharmacol 2008; 61: 607-14.
42. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544-55.